



## Radiofrequency Ablation for Thyroid Tumors: A New Era Principle of Radio Frequency Ablation Begins in Bangladesh






Prepared by Dr. M K Azad FCPS(Medicine),MD (Endocrinology),MPH,DEM Consultant and Head of the Department Department of Endocrinology Government Employee Hospital Fulbaria, Dhaka, Bangladesh









# Traditional guideline of Thyroid Nodule Approach




# Current guideline of Tyroid Nodule Approach



# Updated Guideline of Thyroid Nodule Approach(KJR)





Updated Guideline of Thyroid Nodule Approach(KJR)

# Introduction to Thyroid Nodules

What is Nodule: Over growth of tissue in thyroid

# Nodule vs Tumour ?

- Smaller and less likely malignant vs larger and higher potential for malignancy.
- $\blacktriangleright$  Most are benign; malignancy rate  $\approx$  5–15% vs Higher risk of malignancy or already malignant,



Epidemiology:

**Detection Method** 

## Prevalence

**Clinical palpation** 

Ultrasound (Sonography)

~19%–68%, depending on age, sex, iodine status

~4%–7% of the adult population

**Autopsy studies** 

~30%-60%

Prevalence increases with age, female sex, and in iodine-deficient areas.

The **majority of nodules are benign**, and only about **5%–15% are malignant** based on clinical and cytological assessment.

Scan for getting it



## What happened if leave untreted

## 1. Cancer Risk

•About 5%–15% of nodules may be malignant

•Requires biopsy and follow-up to rule out thyroid cancer

## 2. Pressure Symptoms

Difficulty swallowing

•Neck discomfort or tightness

•Breathing difficulty (especially when lying flat or if retrosternal)

## **3. Hormonal Imbalance**

- Hyperthyroidism if nodule is autonomously functioning (toxic nodule)
- hypothyroidism if part of chronic thyroiditis

## 4. Cosmetic Concerns

Embarrassment or distress due to appearance

## 5. Nodule Growth Over Time

•May enlarge, causing increasing symptoms

•Can require **repeat imaging** and possible **intervention** 

## 6. Anxiety and Uncertainty

- •Fear of cancer or complications
- •Repeated evaluations, biopsies, and follow-ups may cause stress

#### Scan for getting it





# Traditional choice of Treatment: Surgery

Scan for getting it



# **Problem of Surgery**

- Complications Related to Anesthesia
- Infection
- Bleeding and Hematoma
- Damage to Surrounding Structures

Recurrent Laryngeal Nerve InjuryParathyroid Gland Damage

- Scarring and Cosmetic Issues
- •Thyroid Hormone Imbalance
- Recurrence of Nodules
- Psychological Impact
- Cost and Recovery Time

#### Scan for getting it



What's new? Thyroid and Artificial intelligence MITT (minimal invasive Thyroid Treatment)/Minimal invasive surgery)

Scan for getting it







# ADC in Winter

- 2700 bed
- 15000/day in OPD
- 7200/year surgery
- Best success rate organ
   transplantation
- Highest technology for cancer treatment





Busan, S. Korea

Scan for getting it



## MITT

 Endoscopic Thyroidectomy Robotic-Assisted Thyroidectomy •Transoral Thyroidectomy Percutaneous Radiofrequency Ablation (RFA) Laser Ablation •Ethanol Ablation •Microwave Ablation (MWA) •Ultrasound-Guided Biopsy and Ablation Endoscopic Thyroid Lobectomy Minimally Invasive Parathyroidectomy •Radioactive lodine (RAI) Therapy •Thyroid Nodule Cryoablation

Scan for getting it




# What is **RFA**

- RFA is a minimally invasive procedure used to treat tumors and abnormal tissues.
- It utilizes high-frequency alternating current (200-1200 kHz) to generate thermal energy.
- Commonly applied in liver malignancies, thyroid nodules, and other solid tumors.
- Safe and effective alternative to surgery for certain benign and malignant conditions.

aa





# Step-by-step Procedure of RFA

RFA: the new horizon

Scan for getting it



# **Equipment of RFA**

- **1. RFA Generator (Radiofrequency Generator)**
- **2.** Electrodes (RF Needles or Probes)
- **3. Grounding Pads (Return Electrodes)**
- 4. Ultrasound Machine or Imaging Guidance
- 5. Cooling System (for Internally Cooled Electrodes)
- 6. Thermocouples or Temperature Monitoring System (optional)
- 7. Foot Pedal (optional)
- 8. Sterile Consumables and Accessories

Scan for getting it



**Complications and Their** Management **Major Complications** Voice change (hoarseness) – 0.94– 1.6% Nodule rupture – 0.3–1.2% Significant hematoma – 0.2–0.5% Severe skin burn - < 0.1%

**Minor Complications** 

Pain – 2.5–4%

Minor hematoma – 1–2% Transient thyrotoxicosis – <1% Mild skin burn - < 0.5%Infection - < 0.2%Cough/vasovagal reaction – <1% Post-procedure Care and Follow-up

# Post-procedure Care

Immediate Observation (0–1 hour)

Pain and Discomfort ManagementWound and Local CareDischarge Instructions

Follow-up Schedule
•Early Follow-up (1 Month)
•Intermediate Follow-up (3 and 6 Months)
•Long-term Follow-up (12 Months and Beyond)

Scan for getting it



Table 9. Efficacy of RFA for Nonfunctioning Thyroid Nodules								• • .	
Number	Authors	Sample Size (Nodule Number)	Follow Up Period (Months)	Symptom Score at Baselíne	Symptom Score after RFA	Cosmetic Score at Baseline	Nodule Volume at Baseline (mL)	Nodule Volume after Treatment (mL)	VRR (%)
1	Ahn et al. (99)	22 (22)	3.6	NA	NA	NA	14.3	4.7	74.3
2	Aysan et al. (125)	100 (100)	15.4	NA	NA	NA	16.9	2.6	84.6
3	Baek et al. (9)	15 (15)	6.43	3.33	1	3.6	7.5	1.3	82.7
4	Baek et al. (126)	200 (200)	5.21	NA	NA	NA	6.8	1.8	73.2
5	Baek et al. (107)	22 (22)	6	2.9	0.2	3.8	8.6	1.1	87.5
6	Bernardi et al. (57)	37 (37)	12	NA	NA	NA	12.4	3.91	68.4
7	Cesareo et al. (117)	42 (42)	6	2.8	0.4	2.6	24.5	8.6	64.9
8	Che et al. (58)	200 (200)	12	NA	NA	NA	5.4	0.4	84.8
9	Deandrea et al. (132)	40 (40)	6	3.6	0.4	3.6	15.1	4.2	71
10	Hong et al. (101)	18 (18)	18.1	2.4	1.4	3.8	24.4	6.3	74.2
11	Huh et al. (110)	30 (30)	6	5.4	2.1	3.8	13.2	3.4	74.3
12	Jeong et al. (5)	302 (302)	NA	NA	NA	NA	6.13	1.12	84.1
13	Kim et al. (129)	73 (75)	11.5	3.97	1.84	NA	17	6	69.7
14	Kim et al. (6)	35 (35)	6.4	3.4	1.83	NA	6.31	0.74	88.2
15	Li et al. (127)	35 (35)	6	NA	NA	NA	8.81	1.59	82

 Table 2. VRR of RFA of benign thyroid nodules during follow-up

Follow-up length	Overall follow-up nodules* (n = 267)	Overall VRR, %	Multi-session RFA nodules* (n = 87)	Multi-session RFA VRR, %	Single-session RFA nodules* (n = 180)	Single-session RFA VRR, %
<1 yr	265	67.7 (52.7, 82.1)	86	64.5 (52.6, 79.4)	179	68.8 (52.8, 82.9)
1 yr	159	82.5 (69.0, 94.5)	66	80.7 (67.2, 93.2)	93	83.1 (72.7, 94.5)
2 yrs	123	90.7 (82.0, 97.8)	57	89.1 (82.1, 96.6)	66	91.1 (82.0, 98.5)
3 yrs	91	94.3 (85.7, 99.2)	45	90.7 (85.6, 96.9)	46	96.4 (87.4, 100)
4 yrs	75	95.4 (87.9, 100)	37	95.6 (90.0, 99.4)	38	95.1 (87.0, 100)
5 yrs	46	96.2 (91.2, 100)	24	97.5 (90.6, 100)	22	95.8 (91.6, 100)
6 yrs	47	97.5 (91.3, 100)	23	98.2 (90.5, 100)	24	96.4 (91.6, 100)
7 yrs	35	97.8 (92.9, 100)	14	94.3 (89.2, 97.4)	21	100 (95.3, 100)
8 yrs	28	96.5 (93.5, 99.8)	15	96.4 (94.5, 97.3)	13	100 (89.4, 100)
9 yrs	23	99.8 (93.9, 100)	12	97.7 (91.0, 99.8)	11	100 (98.5, 100)
≥10 yrs	32	100 (94.7, 100)	14	100 (94.6, 100)	18	98.8 (95.1, 100)

Data are median (interquartile range).

\*Number of nodules.

VRR = volume reduction rates, RFA = radiofrequency ablation

# **Benefit of RFA over Surgery**

#### Parameter

#### Invasiveness

Anesthesia Hospital Stay Procedure Time

Recovery Time Scar Formation

**Complication Rate** 

**Preservation of Thyroid Function** 

Cost (Korea Data)

**Cosmetic Satisfaction** 

**Re-intervention Option** 

## Radiofrequency Ablation (RFA)

Minimally invasive (needle-based)

Local anesthesia Outpatient or same-day discharge

~30–60 minutes

1–2 days

No visible scar (US-guided)

~3.3% (major: <1.5%)

>95% preserve normal function

Lower total cost

Very high

Repeatable RFA possible if regrowth

## Surgery (Lobectomy or Total Thyroidectomy)

Invasive (incision, general anesthesia)

General anesthesia

2–5 days hospitalization

1.5–2.5 hours

2-3 weeks

Visible neck scar

11–15% (including hypocalcemia, nerve injury)

20–50% require lifelong thyroxine replacement

Higher due to OR, anesthesia, inpatient care

Moderate to low (due to scar)

Limited (once removed, no regrowth possible)

# **RFA vs Microwave ablation**

## Parameter

Mechanism

**Device Control** 

**Heat Propagation** 

**Ablation Volume** 

**Technique Standardization** 

Volume Reduction Rate (12 mo)

**Complication Rate** 

**Nerve Injury Risk** 

**Equipment Availability** 

Cost (Korea)

## Radiofrequency Ablation (RFA)

Ionic agitation via alternating current Precise, temperature-sensitive

Slower, controlled

Smaller per shot, requires moving-shot technique

Well-established moving-shot technique

~80-85%

~3.3% (major <1.5%)

Lower due to slow, controlled heating Widely available, more clinical experience Moderate (well established)

Extensive clinical guidance and training

## **Microwave Ablation (MWA)**

Dielectric heating via microwave energy Rapid and deep heating, less precise control Faster, may affect surrounding tissue Larger per shot, more aggressive heating Lacks standardized technique for thyroid use ~75–83% (comparable, slightly variable) Similar or slightly higher (~3–5% in some studies) Higher if not carefully monitored Less widespread in thyroid centers Similar or slightly higher due to newer technology Shorter learning curve, but lacks thyroid-

# **RFA vs Laser**

Parameter

Mechanism

Needle Type

**Ablation Control** 

Standardization

Volume Reduction Rate (12 mo)

Energy Delivery Complication Rate Cosmetic Outcome Pain During Procedure Procedure Time Post-procedure Recovery Availability in Korea **Radiofrequency Ablation (RFA)** 

Frictional heat from high-frequency current

Internally cooled electrode (18G)

Moving-shot technique (precise targeting)

Well-established for thyroid nodules

~80–85%

Real-time, dynamic control ~3.3% total (major <1.5%) Excellent (no scar) Mild, manageable with local anesthesia ~30–60 minutes 1–2 days Widely used, first-line option Laser Ablation (LA)

Coagulative necrosis from laser light energy Thin optical fibers (21G introducer needle) Fixed-fiber pullback or multi-fiber technique Less standardized for large or complex nodules ~50–75% (variable by nodule size & energy used) Fixed, pulsed energy via fibers ~2–4% (mostly minor) Excellent (no scar) Mild, similar to RFA ~20–40 minutes 1–2 days Less common, used in selected centers

# Role of RFA in Other disorder

## Disorder

AFTN (Autonomous Functional Thyroid Nodules)

## **Recurrent Thyroid Cancer**

## **Role of RFA**

- RFA is a first-line treatment for **non-toxic**, **non-surgical candidates**. - RFA reduces **symptoms** of hyperthyroidism and **nodular size**.

# - RFA offers a **non-surgical approach** to manage **local recurrence** of thyroid cancer after initial surgery.

## Hyperparathyroidism (HP)

 RFA is an alternative to parathyroidectomy for adenomas, especially in cases of secondary hyperparathyroidism in renal failure patients.

# Clinical Data & Outcomes (Korean & European Studies)

 - Volume reduction: ~75–85% after 12 months. -TSH normalization: Achieved in ~90% of cases. -Symptom relief: Over 80% of patients report significant improvement in hyperthyroid symptoms (European Society of Endocrinology, 2020).

- Local control rate: ~70–85% for nodules ≤1.5
 cm. - For small recurrent papillary thyroid cancer,
 RFA has shown similar efficacy to surgery with
 lower complication rates. (KJR, 2019). - Survival
 rates are comparable to those of surgery for
 select recurrent cases (European Thyroid
 Association, 2021).

- PTH reduction: Reduction in PTH levels by 60–70% post-RFA in secondary hyperparathyroidism patients.
 - Success rate: ~70–85% in symptom resolution.
 - RFA has shown a lower complication rate compared to surgery in patients with end-stage renal disease (European Journal of Endocrinology, 2020).

# Mechanism of RFA

Study	Follow-Up Duration	Volume Reduction Rate	Complete Disappearance Rate	Recurrence Rate	Complication Rate
Ten-Year Outcomes Study	Median 133 months	99.9%	91.9%	Not specified	7.7% (transient voice changes)
Systematic Review & Meta- Analysis	≥24 months	95.03%	92%	6%	5%
Longer-Term Outcomes Study	Mean 80 months	99.5%	91.3%	Not specified	None reporting it



# **Contraindications and Cautions**

No Absolute Contraindications

•Lack of any outright "no-go" criteria in current guidelines

•Emphasis on appropriate case selection and technique

Relative Contraindications

Heavy intranodular calcification

Inadequate benign cytology confirmation

•Nodules abutting critical structures ("danger zones")

•Severe coagulopathy or bleeding diathesis

•Special Situations Requiring Modification

•Pregnancy (use of bipolar electrodes)

•Patients with cardiac pacemakers or implanted devices

Scan for getting it






## A GUIDEBOOK ON RADIOFREQUENCY ABLATION FOR THYROID AND NECK TUMOR

A

200

Dr. Back




























# **Conclusion & Acknowledgment**

• Thanks Asan Medical Center for the opportunity



#### Jung Hwan Baek, MD radbaek@naver.com Thyroid and Head & Neck tumor specialist Professor Department of Radiology and Research Institute of Radiology University of Ulsan College of Medicine Asan Medical Center





দেহান দোংনিপ মানসে

• "대한독립 만세!"



dr



# Thank you গাম সাম দা



